# VK2809 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vk2809

> VK2809, sponsored by Viking Therapeutics, Inc. (VKTX): 1 recorded catalyst.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VK2809 |
| Codes | VK2809 |
| Sponsor | Viking Therapeutics, Inc. (VKTX) https://sec-api.dev/companies/vktx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### May 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-02-26, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001193125-26-436432): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-324219): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/vktx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193315): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-046876): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-247059): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-097950): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000095017025097950/vktx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-058129): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000095017025058129/vktx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027824): "In May 2023, we reported positive top-line results from the VOYAGE Phase 2b clinical trial for VK2809 and in June 2024, we announced positive 52-week histologic data from the VOYAGE study." https://www.sec.gov/Archives/edgar/data/1607678/000095017025027824/vktx-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vk2809.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VK2809 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vk2809

```bibtex
@misc{secapidev_pdufa_vk2809_20261116,
  title        = {VK2809 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vk2809}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vk2809_20261116","title":"VK2809 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vk2809","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
